2′-Fucosyllactose (2′-FL) is a ubiquitous oligosaccharide in human milk. Importantly, this carbohydrate promotes the growth of several strains of Bifidobacteria, a class of beneficial gut commensal, and inhibits epithelial binding of pathogens. In light of these protective effects, we elected to evaluate the potential of 2′-FL to serve as an antibacterial agent against Group B Streptococcus (GBS). While 2′-FL was devoid of any substantial antimicrobial or antibiofilm activity, conversion of 2′-FL to its reducing end β-amine provided a novel antibiofilm compound.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2:114–22. https://doi.org/10.1038/nrd1008
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.
Flemming H-C, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8:623–33. https://doi.org/10.1038/nrmicro2415
Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. https://doi.org/10.1111/apm.12099 (2013).
Wu H, Moser C, Wang HZ, Hoiby N, Song ZJ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1–7. https://doi.org/10.1038/ijos.2014.65
Sabir N, et al. Bacterial biofilm-based catheter-associated urinary tract infections: causative pathogens and antibiotic resistance. Am J Infect Control. 2017;45:1101–5. https://doi.org/10.1016/j.ajic.2017.05.009
Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135–8.
Hoiby N, et al. The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3:55–65. https://doi.org/10.4248/IJOS11026
Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. https://doi.org/10.1038/nrmicro821
de Beer D, Stoodley P, Roe F, Lewandowski Z. Effects of biofilm structures on oxygen distribution and mass transport. Biotechnol Bioeng. 1994;43:1131–8. https://doi.org/10.1002/bit.260431118
Ackerman DL, et al. Antimicrobial and antibiofilm activity of human milk oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii. ACS Infect Dis. 2018;4:315–24. https://doi.org/10.1021/acsinfecdis.7b00183
Ackerman DL, et al. Human Milk oligosaccharides exhibit antimicrobial and antibiofilm properties against group B streptococcus. ACS Infect Dis. 2017;3:595–605. https://doi.org/10.1021/acsinfecdis.7b00064
Craft KM, Thomas HC & Townsend SD. Interrogation of human milk oligosaccharide fucosylation patterns for antimicrobial and antibiofilm trends in Group B streptococcus. ACS Infect Dis. https://doi.org/10.1021/acsinfecdis.8b00234 (2018).
Craft KM, Thomas HC & Townsend SD. Sialylated variants of lacto-N-tetraose exhibit antimicrobial activity against Group B Streptococcus. Org Biomol Chem. https://doi.org/10.1039/c8ob02080a (2018).
Craft KM, Gaddy JA, Townsend SD. Human milk oligosaccharides (HMOs) sensitize Group B streptococcus to clindamycin, erythromycin, gentamicin, and minocycline on a strain specific basis. ACS Chem Biol. 2018;13:2020–6. https://doi.org/10.1021/acschembio.8b00661
Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012;22:1147–62. https://doi.org/10.1093/glycob/cws074
Castanys-Munoz E, Martin MJ, Prieto PA. 2’-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutr Rev. 2013;71:773–89. https://doi.org/10.1111/nure.12079
Craft KM & Townsend SD. The human milk glycome as a defense against infectious diseases: rationale, challenges, and opportunities. ACS Infect Dis. https://doi.org/10.1021/acsinfecdis.7b00209 (2017).
Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. Vaccine. 2013;31(Suppl 4):D31–42. https://doi.org/10.1016/j.vaccine.2013.05.012
Cieslewicz MJ, et al. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun. 2005;73:3096–103. https://doi.org/10.1128/IAI.73.5.3096-3103.2005
Morrow AL, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr. 2004;145:297–303. https://doi.org/10.1016/j.jpeds.2004.04.054
Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003;278:14112–20. https://doi.org/10.1074/jbc.M207744200
Markowitz J, et al. Structural characterization of NRAS isoform 5. Protein Sci. 2016;25:1069–74. https://doi.org/10.1002/pro.2916
Koromyslova A, Tripathi S, Morozov V, Schroten H, Hansman GS. Human norovirus inhibition by a human milk oligosaccharide. Virology. 2017;508:81–89. https://doi.org/10.1016/j.virol.2017.04.032
Marotta M, Ryan JT, Hickey RM. The predominant milk oligosaccharide 6′-sialyllactose reduces the internalisation of Pseudomonas aeruginosa in human pneumocytes. J Funct Foods. 2014;6:367–73. https://doi.org/10.1016/j.jff.2013.10.026
Weichert S, et al. Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res. 2013;33:831–8. https://doi.org/10.1016/j.nutres.2013.07.009
del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007;82:204–9. https://doi.org/10.1038/sj.clpt.6100247
Donelli G, Francolini I, Piozzi A, Di Rosa R, Marconi W. New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections. J Chemother. 2002;14:501–7. https://doi.org/10.1179/joc.2002.14.5.501
Meeker DG, et al. Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections. Int J Hyperth. 2018;34:209–19. https://doi.org/10.1080/02656736.2017.1392047
Saini H, Vadekeetil A, Chhibber S & Harjai K. Azithromycin-ciprofloxacin-impregnated urinary catheters avert bacterial colonization, biofilm formation, and inflammation in a murine model of foreign-body-associated urinary tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01906-16 (2017).
Jain T, et al. Biofilm inhibition and anti-Candida activity of a cationic lipo-benzamide molecule with twin-nonyl chain. Bioorg Med Chem Lett. 2018;28:1776–80. https://doi.org/10.1016/j.bmcl.2018.04.024
Perez-Soto N, et al. Engineering microbial physiology with synthetic polymers: cationic polymers induce biofilm formation in Vibrio cholerae and downregulate the expression of virulence genes. Chem Sci. 2017;8:5291–8. https://doi.org/10.1039/c7sc00615b
Algburi A et al. Gemini cationic amphiphiles control biofilm formation by bacterial vaginosis pathogens. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00650-17 (2017).
Takahashi H, Nadres ET, Kuroda K. Cationic amphiphilic polymers with antimicrobial activity for oral care applications: eradication of s. mutans biofilm. Biomacromolecules. 2017;18:257–65. https://doi.org/10.1021/acs.biomac.6b01598
Kreling PF, et al. Cytotoxicity and the effect of cationic peptide fragments against cariogenic bacteria under planktonic and biofilm conditions. Biofouling. 2016;32:995–1006. https://doi.org/10.1080/08927014.2016.1218850
de la Fuente-Nunez C, et al. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother. 2012;56:2696–704. https://doi.org/10.1128/AAC.00064-12
Likhosherstov LM, Novikova OS, Derevitskaja VA, Kochetkov NK. A new simple synthesis of amino sugar beta-D-glycosylamines. Carbohydr Res. 1986;146:C1–C5. https://doi.org/10.1016/0008-6215(86)85037-6
This material is based upon work supported by the National Science Foundation under Grant No. . This work was also supported by Vanderbilt University, the Vanderbilt Microbiome Initiative (VMI), the Department of Pediatrics at Vanderbilt University Medical Center, and Prolacta Bioscience for S.D.T. K.M.C. was supported by the Vanderbilt Chemical Biology Interface (CBI) training program (T32 GM065086), the Vanderbilt Pre3 Initiative (travel grant), and the Mitchum E. Warren, Jr. Graduate Research Fellowship. Prof. Jennifer Gaddy is acknowledged for use of her facilities. Prof. Shannon Manning at Michigan State University is acknowledged for generously providing clinical strains of GBS (GBS590 and GBS2). Harrison Thomas is acknowledged for his assistance with the viability and biofilm assays. Ryan Doster is acknowledged for discussions regarding experimental design. Jacky Lu is acknowledged for his assistance with bacterial culturing.
Conflict of interest
The authors declare that they have no conflict to declare.
Dedication: This manuscript is dedicated to Professor Samuel J. Danishefsky in recognition of his manifold contributions to chemical synthesis, bioorganic chemistry, and the thoughtful mentorship of organic chemists.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Craft, K.M., Townsend, S.D. 1-Amino-2′-fucosyllactose inhibits biofilm formation by Streptococcus agalactiae. J Antibiot 72, 507–512 (2019). https://doi.org/10.1038/s41429-019-0151-6